TET Systems and Novo Nordisk sign license agreement
“We are very glad that we can add the Hagedorn Research Institute as part of Novo Nordisk, one of the premier global pharmaceutical companies with European headquarters, to our growing list of licensees”, stated Dr. E. Böhnlein, CEO of TET Systems. “This license agreement again shows that the Tet Technology provides a clear technological advantage to innovative biomedical research which translates into a strategic advantage for these pharmaceutical and biotech companies.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.